Page 3 - ப்ராடக்ட் சோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ராடக்ட் சோதனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ராடக்ட் சோதனை Today - Breaking & Trending Today

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
April 19, 2021 GMT
Review process started with submission of first CVnCoV data package
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 19, 2021 / The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland. The application for authorization was submitted to Swissmedic, the country’s authority responsible for the authorization and supervision of therapeutic products including vaccines. ....

United States , Antony Blanc , Sarah Fakih , Exchange Commission , European Union , European Medicines Agency , European Commission , Curevac Swiss , Chief Business Officer , Chief Commercial Officer , Latin America , Lipid Nanoparticles , New York Nasdaq , Vice President , Vice President Investor , Public Health , Government Business And Finance , Products And Services , Government Regulations , Coronavirus Pandemic , Product Testing , Government Contracts , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic ,

Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis

Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
April 19, 2021 GMT
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST) ....

New York , United States , Boston University , France General , Pbruce Sands , Burrillb Crohn , Enregistrement Universel , Henryd Janowitz Division Of Gastroenterology , Icahn School Of Medicine At Mount Sinai , Hospital Of The University Pennsylvania , Harvard Medical School , Euronext Paris , Eastern Time , Icahn Scool , Mount Sinai , New York City , Icahn School , New England Journal , Massachusetts General Hospital , Acting Chief , Gastrointestinal Unit , French Autorit , Des March , Corporate News , Products And Services , Health Care Industry ,

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium .
Avadel Pharmaceuticals plcApril 17, 2021 GMT
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses
DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug U ....

United States , Jennifer Gudeman , Tom Mchugh , Patrick Bursey , Avadel Micropump , Michaelj Thorpy , Tim Mccarthy , Lifesci Advisors , Avadel Pharmaceuticals , American Academy Of Neurology Annual , Albert Einstein College Of Medicine , Drug Administration , Wake Disorders Center At Montefiore Medical , Exchange Commission , Clinical Affairs At Avadel , Lifesci Communications , Securities Exchange , Neurology Annual , Prescription Drug User Fee Act , Sleep Wake Disorders Center , Montefiore Medical Center , Albert Einstein College , Vice President , Clinical Affairs , Sleep Continuity , Results From ,

Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific's Brain Mapping Technology

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
EhaveApril 16, 2021 GMT
MIAMI, April 16, 2021 (GLOBE NEWSWIRE) Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders.
The trial, which is designed to enroll 35 patients, is expected to start in the second half of 2021. Ehave is currently completing the necessary preclinical studies necessary to begin enrolling patients in the trial. The average drop out ratio of clinical trials is around 15 % and Ehave will need at least 25-30 patients’ ....

United States , Region Flamande , Manideep Gopishetty , Gabe Rodriguez , Ben Kaplan , Risk Factors In Ehave Inc , Drug Administration , Brain Scientific Inc , Exchange Commission , Additional Ehave Inc , Ehave Inc , Spravato To Janssen Pharmaceuticals Inc , Brain Scientific , Major Refractory , Janssen Pharmaceuticals , Medical Advisor , Chief Medical Officer , Ehave Telemetry Portal , Ehave Infinity Portal , Private Securities Litigation Reform Act , Registration Statement , Products And Services , Government Regulations , Drug Approvals , Coronavirus Pandemic , Product Approvals ,

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

Press release content from PR Newswire. The AP news staff was not involved in its creation.
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
April 16, 2021 GMT
Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)
THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. ....

United States , Puerto Rico , South Korea , Megan Fox , Roberta Bradway , Exchange Commission , Franklin Acquisition Sub Inc , Therapeutics Inc , Five Prime Therapeutics , Five Prime , Latin America , Franklin Acquisition Sub , Thousand Oaks , Public Health , Products And Services , Government Regulations , Ownership Changes , Coronavirus Pandemic , Product Approvals , Product Testing , Health Care Industry , Pr Newswire , Lung Disease , New Products And Services , Medical Research , Mergers And Acquisitions ,